Exploration of Asthma & Allergy

From: Multidimensional super-response to omalizumab in a patient with N-ERD: 9-year follow-up of a case report

Table 1. Parameters of the analyzed case before treatment, 4 months and 9 years of treatment with omalizumab.

Variables	Before treatment	After 4-month-treatment	After 9-year-treatment
BMI (kg/m²)	20.5	20.1	20.7
Eosinophils (%) (normal range: 1.00–5.00)	3.4	4.6	6.3
Eosinophils (1.0 × 10³/μL) (normal range: 0.0–0.5 × 10³/μL)	0.22	0.32	0.48
Total IgE (IU/mL)	1,007	590	230
FEV₁/FVC (%)	66	62	70
FVC (%)	86	89	93
FEV₁ (%)	66	67	69
ACQ (points)	4.8	2.3	0
AQLQ (points)	1.6	6.9	6.4
SNOT-22 (points)	87	23	2
TNSS (points)	14	6	1
NPS (points)	8	0	0
Sense of smell	Absent	Present	Present
Intranasal fluticasone (µg daily)	400	400	0
Inhaled fluticasone (µg inhaled daily)	1,000	500	0
Inhaled salmeterol (µg inhaled daily)	100	50	0
Wheel-of-Life (points)	11	52	77

Return to article view

Abbreviations: ACQ: Asthma Control Questionnaire; AQLQ: Asthma Quality of Life Questionnaire; NPS: nasal polyp score; SNOT: Sino-Nasal Outcome Test; TNSS: Total Nasal Symptom Score; FEV₁: forced expiratory volume in 1st second; FVC: forced vital capacity.

Declarations

Author contributions

EJS: Conceptualization, Investigation, Writing—original draft. JG: Conceptualization, Investigation, Writing—original draft, Writing—review & editing. RG: Investigation, Writing—review & editing, Supervision. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The study complies with the Declaration of Helsinki. Ethical approval from the Bioethics Committee is not required at our university for case reports.

Consent to participate

Informed consent to participate in the study was obtained from the patient.

Consent to publication

Informed consent to publication was obtained from the patient.

Availability of data and materials

The datasets for this study are available from the corresponding author upon reasonable request.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

The WHOQOL Group. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41:1403–9. [DOI] [PubMed]

Delpierre C, Lefèvre T. Precision and personalized medicine: What their current definition says and silences about the model of health they promote. Implication for the development of personalized health. Front Sociol. 2023;8:1112159. [DOI] [PubMed] [PMC]

Kariyawasam HH, Chandrasekharan DP, Jacques T, Stokes P, Dziadzio M, Gane SB, et al. Biologic treatment for severe chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis. Rhinology. 2023;61:98–107. [DOI] [PubMed]

Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58:1–464. [DOI] [PubMed]

Stevens WW, Peters AT, Tan BK, Klingler AI, Poposki JA, Hulse KE, et al. Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis. J Allergy Clin Immunol Pract. 2019;7:2812–20.e3. [DOI] [PubMed] [PMC]

Fokkens WJ, Viskens AS, Backer V, Conti D, De Corso E, Gevaert P, et al. EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinology. 2023;61:194–202. [DOI] [PubMed]

Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol. 2015;135:676–81.e1. [DOI] [PubMed]

van der Lans RJL, Fokkens WJ, Reitsma S. Therapeutic Options for Chronic Rhinosinusitis in N-ERD Patients. Front Allergy. 2021;2:734000. [DOI] [PubMed] [PMC]

Kowalski ML, Agache I, Bavbek S, Bakirtas A, Blanca M, Bochenek G, et al. Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper. Allergy. 2019;74:28–39. [DOI] [PubMed]

10.

Portal Gov.pl [Internet]. [cited 2025 Sep 25]. Available from: https://www.gov.pl/attachment/0ca7e3df-f174-41ba-9930-3c0260a704aa

11.

Highlights of prescribing information [Internet]. [cited 2025 Sep 25]. Available from: https://www.gene.com/download/pdf/xolair_prescribing.pdf

12.

Whitworth L, Kimsey-House H, Kimsey-House K, Sandahl P. Co-Active Coaching: New Skills for Coaching People Toward Success in Work and Life (2nd ed.). Davies-Black Publishing; 2007.

13.

Stevens WW, Peters AT, Hirsch AG, Nordberg CM, Schwartz BS, Mercer DG, et al. Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract. 2017;5:1061–70.e3. [DOI] [PubMed] [PMC]

14.

Stankiewicz JA, Lal D, Connor M, Welch K. Complications in endoscopic sinus surgery for chronic rhinosinusitis: a 25-year experience. Laryngoscope. 2011;121:2684–701. [DOI] [PubMed]

15.

Van Broeck D, Steelant B, Scadding G, Hellings PW. Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)? Front Allergy. 2023;4:1080951. [DOI] [PubMed] [PMC]

16.

Forster-Ruhrmann U, Stergioudi D, Pierchalla G, Fluhr JW, Bergmann KC, Olze H. Omalizumab in patients with NSAIDs-exacerbated respiratory disease. Rhinology. 2020;58:226–32. [DOI] [PubMed]

17.

Tepetam FM, Özden Ş, Kılıç FK, Örçen C, Yakut T. Does NSAID exacerbated respiratory disease (N-ERD) accompanying severe asthma affect biological treatment response? Efficacy of omalizumab and mepolizumab in N-ERD. World Allergy Organ J. 2023;16:100817. [DOI] [PubMed] [PMC]

18.

Quint T, Dahm V, Ramazanova D, Arnoldner MA, Kurz H, Janik S, et al. Omalizumab-Induced Aspirin Tolerance in Nonsteroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease Patients Is Independent of Atopic Sensitization. J Allergy Clin Immunol Pract. 2022;10:506–16.e6. [DOI] [PubMed]

19.

Upham JW, Le Lievre C, Jackson DJ, Masoli M, Wechsler ME, Price DB; Delphi Panel. Defining a Severe Asthma Super-Responder: Findings from a Delphi Process. J Allergy Clin Immunol Pract. 2021;9:3997–4004. [DOI] [PubMed]